Lilly's weight loss pills were accused of rebounding after discontinuation, and the company's stock price plummeted at one point
桃花朵朵149
发表于 2023-12-12 14:11:53
1349
0
0
According to the Red Star Capital Bureau, the stock price of weight loss drug giant LY. US fell at the beginning of trading on December 11th local time, with a drop of over 5% during the trading session. The subsequent decline has eased. As of the close, it fell 2.34% to $584.04 per share, with a total market value of $554.4 billion.
On the news side, according to a report by Caixin, a study published in the Journal of the American Medical Association showed that after using Eli Lilly's weight loss drug Zepbound for about eight months and discontinuing administration, the weight of the subjects slowly rebounded, and the weight lost increased by half again one year later.
Specifically, 670 patients lost 20.9% of their weight after approximately 8 months of using Zepbound. Afterwards, half of the patients continued to receive Zepbound for another year, while the other half received placebo.
The data shows that patients who continued to receive Zepbound had an average weight loss of 5.5%, while the other half of patients who received placebo had an average weight gain of 14%.
Red Star Capital Bureau noted that on November 9, Lilly announced that the company's tirzepatide injection (trade name: Zepbound) was approved by the U.S. Food and Drug Administration (FDA) and was applicable to long-term weight management of overweight adults who were obese or had at least one complication (such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea or cardiovascular disease).
The main ingredient of Zepbound is Tilpatide, which, according to Lilly, is the first and currently the only approved drug that can activate two types of intestinal trypsin receptors (GIP and GLP-1), targeting the root cause of weight gain. According to reports, Novo Nordisk's (NVO.US) semaglutide only targets GLP-1.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Domestic innovative drug leader faces another 'patent challenge': AbbVie accuses BTK degradation agent of infringement, causing BeiGene's stock price to suffer a setback
- Trump Media's stock price has fallen by 70% since going public, experts say valuation is still 'unreasonably high'!
- Global markets: European and American stock markets close down, Nasdaq falls more than 1%, ASML stock price drops more than 16%
- Top 20 US Stock Transactions: Netflix's Strong Performance, Stock Price Rises 11% to Record High
- Google's third quarter report is expected to reveal significant fluctuations in stock price, which may be difficult to avoid
- Apple invests $1.5 billion to increase its stake in satellite communications, causing a surge in global satellite stock prices
- The stock price of Trump Media Technology Group rose by over 15% after the US stock market closed
- Suddenly changed! Big news from chip giants! Samsung Electronics' stock price rises
- The stock price of Supermicro Computer has surged by 40%! What happened?
- Novo Nordisk's stock price returns to its starting point at the beginning of the year! Falling sales of weight loss drugs scare off investors
-
11月21日、2024世界インターネット大会烏鎮サミットで、創業者、CEOの周源氏が大会デジタル教育フォーラムとインターネット企業家フォーラムでそれぞれ講演、発言したことを知っている。周源氏によると、デジタル教 ...
- 不正经的工程师
- 1 小时前
- 支持
- 反对
- 回复
- 收藏
-
アリババは、26億5000万ドルのドル建て優先無担保手形と170億元の人民元建て優先無担保手形の定価を発表した。ドル債の発行は2024年11月26日に終了する予定です。人民元債券の発行は2024年11月28日に終了する予定だ ...
- SOGO
- 前天 09:05
- 支持
- 反对
- 回复
- 收藏
-
スターバックスが中国事業の株式売却の可能性を検討していることが明らかになった。 11月21日、外国メディアによると、スターバックスは中国事業の株式売却を検討している。関係者によると、スターバックスは中国事 ...
- 献世八宝掌
- 昨天 16:29
- 支持
- 反对
- 回复
- 收藏
-
【意法半導体CEO:中国市場は非常に重要で華虹と協力を展開】北京時間11月21日、意法半導体(STM.N)は投資家活動の現場で、同社が中国ウェハー代工場の華虹公司(688347.SH)と協力していると発表した。伊仏半導体 ...
- 黄俊琼
- 昨天 14:29
- 支持
- 反对
- 回复
- 收藏